• Arikace™ is a sustained-release lipid formulation of amikacin for inhalation, being developed for lung infections due to susceptible pathogens
• Key Features of Arikace™ -Charge neutral highly biocompatible liposomes (~0.3 m) packed with amikacin -Penetration of drug into biofilm -High lung Cmax, AUC, and t½ Improved AUC: MIC ratio -Potent PsA killing, including resistant isolates -Virulence factors secreted by Pseudomonas facilitate further release of amikacin from Arikace™ -Normal BAL macrophage activity -Toxicology in dogs and rats (3-6 months) supports long-term clinical studies 
Arikace™ -Summary and Conclusions
 Arikace™ administered once daily using eFlow® has been welltolerated for 4 cycles  Data show statistically significant reduction in P. aeruginosa density including mucoid strains, that has been sustained over the 12 month study period  No significant shift was observed in MICs  Nebulization of 560 mg of Arikace™ once daily for 28 days followed by 56 days off-treatment for 4 cycles demonstrated improvement in lung function that is sustained during the two months off study drug. This treatment effect has been maintained in each of the 4 cycles over a 12 month period with statistically significant increase in FEV 1 over time (p=<0.0001)  Subjects continue in this study towards completion of 6 cycles (18 months)  Preparations are underway to launch Phase 3 studies
